产品
编 号：F102791
分子式：C28H41N3O3
分子量：467.64
分子式：C28H41N3O3
分子量：467.64
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 126-27-2
产品详情
生物活性：
Oxethazaine (Oxetacaine), a precursor of phentermine?acidic, is an acid-resistent and orally active analgesic agent. Oxethazaine (Oxetacaine) has the potential for the relief of pain associated with?peptic ulcer disease?or?esophagitis.
体内研究：
Oxetacaine (intraperitoneal?injection; 5, 10, and 15 mg/kg; during days 4–11) doses induces significant conditioned place preference (CPP), and there are no differences among the groups. While its postive control group phentermine only 3 mg/kg causes significant CPP..Animal Model:Male Wistar rats
Dosage:5, 10, and 15 mg/kg; during days 4–11
Administration:Intraperitoneal?injection
Result:Showed a significant CPP in vivo.
Oxethazaine (Oxetacaine), a precursor of phentermine?acidic, is an acid-resistent and orally active analgesic agent. Oxethazaine (Oxetacaine) has the potential for the relief of pain associated with?peptic ulcer disease?or?esophagitis.
体内研究：
Oxetacaine (intraperitoneal?injection; 5, 10, and 15 mg/kg; during days 4–11) doses induces significant conditioned place preference (CPP), and there are no differences among the groups. While its postive control group phentermine only 3 mg/kg causes significant CPP..Animal Model:Male Wistar rats
Dosage:5, 10, and 15 mg/kg; during days 4–11
Administration:Intraperitoneal?injection
Result:Showed a significant CPP in vivo.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备